Astrolab Newsletters

To subscribe to the Astrolab newsletter, please click on the link below:
To suppress your name from the mailing list, please click on the link below:



 ASTROLAB Symposium 

The ASTROLAB final symposium took place on the 14th of April 2016 in Lyon, organized jointly with the REG Annual Summit (15th and 16th April 2016).

The programme is available HERE





83 attendees registered for the Symposium from 14 different countries: France, the UK, Sweden, Spain, the Netherlands, USA, Singapore, Canada, Belgium, Germany, Czech Republic, Bulgaria, Philippines, Switzerland. The high participation to the event shows the large interest around the question of the safety of LABAs in asthma care and to the related issues.



All attendees received a delegate’s bag with the ASTROLAB booklet, available HERE.

A quiz was distributed to the attendees in the morning. The audience enjoyed this exercise with high participation rate. Results, available HERE, were presented at the end of the day and showed that presentations and discussions helped to fill knowledge gaps.

It was a unique opportunity to share the project results and discuss common solutions for improving asthma care in Europe. The consortium thanks again all attendees for their interest and received feedback that will be taken into consideration in the preparation of the final reports of the project.

About the ASTROLAB project  

The project is funded by the European Commission (EC) through the Seventh Framework Program (FP7) under Grant Agreement n° 282 593 (Assessment of the LABAs benefit/risk ratio in asthma in routine care by combining healthcare databases and direct patient follow-up) and will run for 4 years (2011-2015). It includes 7 partners in a Consortium (Université Claude Bernard Lyon 1, University of Nottingham, Kappa Santé SAS, Cegedim Strategic Data Medical Research Limited, Universiteit van Amsterdam, Consortio Mar Parc de Salut de Barcelona, Lyon Ingénierie Projets).

The ASTRO-LAB project aims to provide new  information about the benefit/risk ratio of long-acting bronchodilators (LABAs, also known as long-acting relievers). It addresses several important knowledge gaps by focusing on both adults and young people with asthma, and on the benefit/risk ratio of LABAs taken with Inhaled Corticosteroids (ICs, also known as controllers). We also examine how people with asthma use LABAs and ICs inhalers, what influences their decisions on how they use inhalers, the care they receive from their clinicians, and what determines how their clinicians help them manage their asthma. 

The ASTRO-LAB protocol has been approved by regulatory authorities in the UK and in France.  Authorizations are available here.